New cocktail of drugs takes on deadly pancreatic cancer

NCT ID NCT07235930

Recruiting now Disease control Sponsor: Zhejiang Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a sequence of chemotherapy drugs plus two immunotherapy and anti-angiogenesis drugs works better than standard chemotherapy alone for people with advanced pancreatic cancer that cannot be removed by surgery. About 292 participants in China will be randomly assigned to one of two groups. The goal is to see if the new combination helps people live longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nab-paclitaxel, gemcitabine, 5-FU, oxaliplatin, leucovorin, serplulimab, and bevacizumab
What this could lead to: If successful, this combination could extend survival for people with advanced pancreatic cancer who have not had prior treatment.
What could go wrong: This is a Phase III trial, but the new combo adds more drugs, which may increase side effects. It may not prove better than standard chemo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-RESECTABLE PANCREAS CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-RESECTABLE PANCREAS CARCINOMA

Contacts and locations

Locations

Zhejiang Cancer Hospital
RECRUITING

Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.